Source: Respiratory Failure and Mechanical Ventilation Conference 2020
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
O. Shtepa (Dnipro, Ukraine). Impact of the phosphatidylcholine treatment program on the respiratory failure in patients with community-acquired pneumonia. Respiratory Failure and Mechanical Ventilation Conference 2020

Member's Comments

No comment yet.

Related content which might interest you: Cost of treatment failure in community-acquired pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 195s Year: 2007 Community-acquired pneumonia as a cause of acute respiratory failure (ARF) in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 518s Year: 2005 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007 Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Lower respiratory tract infections: when are antibiotics mandatory? Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=146 Year: 2004 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Prevention of nosocomial infections in acute respiratory failure patients Source: Eur Respir J 2003; 22: 72S-76S Year: 2003 Heliox-therapy of patients with execerbation of COPD and community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 106s Year: 2006 Treatment failure of severe and ventilator-associated pneumonia Source: Annual Congress 2012 - PG17 Clinical failure of treatment of respiratory infections Year: 2012 Characteristics of pnemococcal community-acquired pneumonia presenting with respiratory failure Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Management-based risk prediction in community-acquired pneumonia by scores and biomarkers Source: Eur Respir J 2013; 41: 974-984 Year: 2013 Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients Source: Annual Congress 2011 - COPD management Year: 2011 Impact of nosocomial pneumonia on the outcome of mechanically-ventilated patients Source: Eur Respir J 2004; 24: Suppl. 48, 548s Year: 2004 Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 Mixed community-acquired pneumonia in hospitalised patients Source: Eur Respir J 2006; 27: 795-800 Year: 2006 The comparison of hospitalized healthcare-associated pneumonia with community-acquired pneumonia patients Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients Year: 2010 Clinical failure in community-acquired pneumonia Source: International Congress 2014 – PG16 Low respiratory tract infections: learning from real clinical cases Year: 2014 Severity assessment of healthcare-associated pneumonia and pneumonia in immunosuppression Source: Eur Respir J 2012; 40: 1201-1210 Year: 2012 Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009